John J Engelhardt

Title: John J Engelhardt: Innovator in Immunotherapy

Introduction

John J Engelhardt is a prominent inventor based in Fremont, CA (US), known for his significant contributions to the field of immunotherapy. With a total of six patents to his name, Engelhardt has made strides in developing innovative therapeutic solutions that enhance immune responses.

Latest Patents

One of Engelhardt's latest patents is focused on Anti-ICOS agonist antibodies and their uses. This invention provides isolated monoclonal antibodies that bind to human Inducible T Cell COStimulator (ICOS) and exhibit desirable functional properties. These antibodies can stimulate human ICOS activity, which is crucial for enhancing immune responses. The patent also includes nucleic acid molecules encoding these antibodies, expression vectors, and methods for expressing them. Furthermore, Engelhardt's invention encompasses immunoconjugates, bispecific molecules, and pharmaceutical compositions that utilize these antibodies. They can be employed as agonists to stimulate antigen-specific T cell responses against tumors or viral antigens. Additionally, these antibodies can be used in combination with other therapeutic antibodies to treat cancer, showcasing their potential in therapeutic applications.

Career Highlights

Engelhardt's career is marked by his work at Bristol-Myers Squibb Company, where he has been instrumental in advancing research in immunotherapy. His innovative approach and dedication to enhancing immune responses have positioned him as a key figure in the field.

Collaborations

Engelhardt has collaborated with notable colleagues, including Mark J Selby and Alan J Korman. These partnerships have further enriched his research and contributed to the development of groundbreaking therapeutic solutions.

Conclusion

John J Engelhardt's work in immunotherapy exemplifies the impact of innovation in medicine. His patents and collaborations reflect a commitment to advancing healthcare through scientific discovery.